Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

50.94
+1.653.35%
Pre-market: 50.54-0.4000-0.79%09:07 EDT
Volume:1.94M
Turnover:98.43M
Market Cap:4.04B
PE:6.78
High:51.65
Open:49.33
Low:49.33
Close:49.29
Loading ...

PTC Therapeutics (PTCT) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
29 Jul

These Analysts Increase Their Forecasts On PTC Therapeutics

Benzinga
·
29 Jul

UBS Adjusts Price Target on PTC Therapeutics to $80 From $71, Maintains Buy Rating

MT Newswires Live
·
29 Jul

PTC Therapeutics Receives Buy Rating Following FDA Approval of Sephience and Strategic Market Positioning

TIPRANKS
·
29 Jul

TD Cowen Remains a Hold on PTC Therapeutics (PTCT)

TIPRANKS
·
29 Jul

PTC Therapeutics: Buy Rating Driven by Sephience Approval and Market Strategy

TIPRANKS
·
29 Jul

PTC Therapeutics, Inc. : Wells Fargo Raises Target Price to $78 From $74

THOMSON REUTERS
·
29 Jul

Positive Outlook for PTC Therapeutics’ Sephience: Strong Market Potential and Revenue Prospects

TIPRANKS
·
29 Jul

PTC Therapeutics : Barclays Raises Target Price to $46 From $42

THOMSON REUTERS
·
29 Jul

PTC Therapeutics price target raised to $46 from $42 at Barclays

TIPRANKS
·
29 Jul

U.S. RESEARCH ROUNDUP-Blackline, Cadence Design Systems, Coinbase Global

Reuters
·
29 Jul

PTC Therapeutics Inc : Jefferies Raises Target Price to $64 From $60

THOMSON REUTERS
·
29 Jul

PTC Therapeutics Inc. Unveils Corporate Presentation Highlighting 2024 Achievements and Future Plans for Rare Disease Therapies

Reuters
·
29 Jul

PTC Therapeutics Gains FDA Approval for Sephience

TIPRANKS
·
29 Jul

PTC Therapeutics trading resumes

TIPRANKS
·
29 Jul

US FDA approves PTC Therapeutics' metabolic disorder drug

Reuters
·
29 Jul

PTC Therapeutics Receives FDA Approval for SEPHIENCE™ to Treat Phenylketonuria; European Commission Grants Marketing Authorization

Reuters
·
29 Jul

PTC Therapeutics Announces FDA Approval of Sephience™ (Sepiapterin) for the Treatment of Children and Adults Living With Phenylketonuria (Pku)

THOMSON REUTERS
·
29 Jul

PTC Therapeutics Is Maintained at Neutral by Citigroup

Dow Jones
·
29 Jul

PTC Therapeutics Inc : Citigroup Raises Target Price to $50 From $40

THOMSON REUTERS
·
28 Jul